Acorda Therapeutics Inc (ACORQ)

Currency in USD
0.014
0.000(0.00%)
Closed·
Showing Acorda historical data. For real-time data please try another search
Fair Value
Day's Range
0.0140.014
52 wk Range
0.01314.110
Key Statistics
Prev. Close
0.014
Open
0.014
Day's Range
0.014-0.014
52 wk Range
0.013-14.11
Volume
-
Average Volume (3m)
22.11K
1-Year Change
-49.96%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACORQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Acorda Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Acorda Therapeutics Inc Company Profile

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. The plan was later approved as Chapter 11 liquidation on August 7, 2024.

Compare ACORQ to Peers and Sector

Metrics to compare
ACORQ
Peers
Sector
Relationship
P/E Ratio
0.0x−1.4x−0.5x
PEG Ratio
0.000.030.00
Price/Book
0.0x1.4x2.6x
Price / LTM Sales
0.0x1.8x3.3x
Upside (Analyst Target)
0.0%349.0%43.4%
Fair Value Upside
Unlock9.5%7.1%Unlock

Earnings

Latest Release
May 14, 2024
EPS / Forecast
-22.06 / --
Revenue / Forecast
20.29M / --
EPS Revisions
Last 90 days

ACORQ Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.